Equasens (PHF) Stock Price & Analysis
PHF Stock Chart & Stats
- Day’s Range
- EUR 28.10 - EUR 29.55
- 52-Week Range
- EUR 27.10 - EUR 44.40
- Previous Close
- EUR 29.55
- Volume
- N/A
- Average Volume (3M)
- 7
- Market Cap
- EUR 401.80M
- Enterprise Value
- EUR 519.20M
- Total Cash (Recent Filing)
- EUR 69.00M
- Total Debt (Recent Filing)
- EUR 57.08M
- Price to Earnings (P/E)
- 9.9
- Beta
- 0.49
- Next Earnings
- Mar 26, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 4.60%
Bulls Say, Bears Say
Bulls Say
Durable Profitability
Equasens maintains strong profitability, with net margins generally in the high-teens to low-20s and operating margin near 20% in 2025. This indicates an established software and services model capable of producing meaningful earnings while supporting reinvestment and shareholder returns.
Balance-sheet Resilience
Improving leverage and expanding equity provide Equasens with a more resilient financial base. Moderate debt reduces pressure on cash resources, while healthy returns on equity show that the company continues to generate attractive profits from its shareholder capital over the medium term.
Strong Cash Generation
Equasens generates substantial cash from operations, with approximately 59.2M of operating cash flow and 47.1M of free cash flow in 2025. This cash generation can support product investment, business development, dividends, and balance-sheet resilience without relying solely on external financing.
Bears Say
Margin Compression
Although profitability remains solid, the decline in margins from the stronger 2021–2023 period indicates that earnings are not expanding as efficiently as before. Continued compression could reduce operating leverage, limit reinvestment capacity, and make future profit growth more dependent on revenue expansion.
Slower Revenue Growth
The move from stronger earlier growth to a decline in 2024 and only a moderate rebound in 2025 suggests less consistent demand expansion. Slower top-line growth can constrain operating leverage and make it harder for Equasens to offset cost pressures while sustaining its historical profitability.
Declining Free-cash-flow Growth
Strong absolute free cash flow is tempered by three consecutive years of negative growth, indicating that cash generation has not kept pace with prior levels. If this trend persists, Equasens may have less incremental funding available for expansion, technology investment, or shareholder distributions.
Equasens News
PHF FAQ
What was Equasens’s price range in the past 12 months?
What is Equasens’s market cap?
When is Equasens’s upcoming earnings report date?
How were Equasens’s earnings last quarter?
Is Equasens overvalued?
Does Equasens pay dividends?
What is Equasens’s EPS estimate?
How many shares outstanding does Equasens have?
What happened to Equasens’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Equasens?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Equasens
Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their networks with advanced management systems, including LGPI global services and OffiCentral. Pharmacists leverage a comprehensive suite of tools designed to streamline daily business operations, such as OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker. To foster stronger customer relationships and engagement, Equasens provides innovative solutions like OffiTag, OffiTouch, OffiMédia, OffiConnect, alongside automation systems and loyalty program management. Beyond operational software, the company offers analytical insights through its My Pilot tool and professional development opportunities via OffiLearning, an e-learning platform. A key area of focus is patient support, with offerings spanning compliance monitoring software, Multimeds, Automeds, OffiTéléconsult, and essential pharmaceutical and shared medical record services. The company's specialized systems include ULTIMATE, which combines efficient pharmacy administration with enhanced patient care, and FARMACLICK, a protocol facilitating communication between pharmacies and wholesale distributors (the latter also served by DIFARM). Additional retail management tools comprise PHARE and the SOPHIA pharmacy application, complemented by OffiMédia POS displays. Equasens also addresses specific health needs, such as chronic renal failure management with eNephro, and simplifies the administration of patient education programs through TPE Pilot. Further extending its reach across the healthcare sector, Equasens offers various dedicated solutions like NOVIACARE, CARELIB (for home and nursing home care), KAPELSE, TITAN, ANTHADINE software, the MOBISOINS mobile tool, MICROSOINS for in-home nursing care, and LOGICLIC. For holistic patient journey oversight, the AXIGATE solutions and CHORUS platform are available. Supplementary services include medical telesecretarial assistance for healthcare professionals and equipment lease financing options. Equasens S.A. functions as a subsidiary of Marque Verte Sante.
- Sector
- General
- Industry
- Software - Application
- CEO
- Denis Supplisson
- Employees
- 1,462
- Website
- equasens.com
- Address
- 5 AllEe de Saint Cloud, Villers-lès-Nancy, GE, 54600, FR
Equasens (PHF) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 3 | 10 |
| Technical Analysis | 2 | 3 | 4 |
| Moving Averages | 6 | 0 | 6 |








